» Articles » PMID: 10804293

Photodynamic Inactivation with Acridine Orange on a Multidrug-resistant Mouse Osteosarcoma Cell Line

Overview
Specialty Oncology
Date 2000 May 11
PMID 10804293
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Overcoming multidrug resistance (MDR) is an urgent issue to improve the prognosis of osteosarcoma patients. In this study, we undertook to clarify the effect of photodynamic therapy (PDT) with acridine orange (AO) on the MDR mouse osteosarcoma (MOS / ADR1) cell line, by comparing the outcome with the effect on a chemosensitive osteosarcoma (MOS) cell line. Cultured cells of MOS and MOS / ADR1 cell lines were exposed to AO at various concentrations for various times, followed by long- or short-term (10 or 1 min) illumination with blue light (466.5 nm) for excitation. Living cells were counted by means of the trypan blue exclusion test. The results showed that AO rapidly bound to DNA, RNA and lysosomes of living MOS and MOS / ADR1 cells and also that most tumor cells in both cell lines died rapidly (viability ratio to untreated cells: 1/1000) within 48 h under conditions of continuous or 15-min flash exposure to AO at concentrations above 1.0 microg/ml plus 10-min illumination with blue light. Even after flash exposure to AO at concentrations above 1.0 microg/ml plus 1-min illumination, the viability of MOS/ADR1 cells decreased to a viability ratio of less than 1/ 1000 within 72 h. Based on these results, we concluded that AO with photo-excitation has a strong cytocidal effect, not only on chemosensitive mouse osteosarcoma cells, but also on MDR mouse osteosarcoma cells. These results suggested that photodynamic therapy with AO may be a new approach to treating MDR human osteosarcomas.

Citing Articles

Radiodynamic Therapy with Acridine Orange Is an Effective Treatment for Bone Metastases.

Di Pompo G, Kusuzaki K, Ponzetti M, Leone V, Baldini N, Avnet S Biomedicines. 2022; 10(8).

PMID: 36009451 PMC: 9405350. DOI: 10.3390/biomedicines10081904.


Isocyanide Substitution in Acridine Orange Shifts DNA Damage-Mediated Phototoxicity to Permeabilization of the Lysosomal Membrane in Cancer Cells.

Banko C, Nagy Z, Nagy M, Szeman-Nagy G, Rebenku I, Imre L Cancers (Basel). 2021; 13(22).

PMID: 34830806 PMC: 8616321. DOI: 10.3390/cancers13225652.


Progress of Phototherapy Applications in the Treatment of Bone Cancer.

Sun J, Xing F, Braun J, Traub F, Rommens P, Xiang Z Int J Mol Sci. 2021; 22(21).

PMID: 34768789 PMC: 8584114. DOI: 10.3390/ijms222111354.


Mesenchymal stromal cells mediated delivery of photoactive nanoparticles inhibits osteosarcoma growth in vitro and in a murine in vivo ectopic model.

Lenna S, Bellotti C, Duchi S, Martella E, Columbaro M, Dozza B J Exp Clin Cancer Res. 2020; 39(1):40.

PMID: 32087737 PMC: 7036176. DOI: 10.1186/s13046-020-01548-4.


The role of photodynamic therapy on multidrug resistant breast cancer.

Aniogo E, George B, Abrahamse H Cancer Cell Int. 2019; 19:91.

PMID: 31007609 PMC: 6458738. DOI: 10.1186/s12935-019-0815-0.


References
1.
Tatsuta M, Yamamura H, Yamamoto R, Ichii M, Noguchi S, Iishi H . Destruction of implanted gastric tumors in rats by acridine orange photoactivation with an argon laser. Eur J Cancer Clin Oncol. 1984; 20(4):543-52. DOI: 10.1016/0277-5379(84)90241-4. View

2.
Baguley B, Ferguson L . Verapamil modulates mutagenicity of antitumour acridines in bacteria and yeast. Biochem Pharmacol. 1986; 35(24):4581-4. DOI: 10.1016/0006-2952(86)90784-7. View

3.
Bacci G, Picci P, Ruggieri P, Mercuri M, Avella M, Capanna R . Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and.... Cancer. 1990; 65(11):2539-53. DOI: 10.1002/1097-0142(19900601)65:11<2539::aid-cncr2820651125>3.0.co;2-m. View

4.
Iwamoto Y, Itoyama T, Yasuda K, Morita T, Shimizu T, Masuzawa T . Photodynamic DNA strand breaking activities of acridine compounds. Biol Pharm Bull. 1993; 16(12):1244-7. DOI: 10.1248/bpb.16.1244. View

5.
Takeshita H, Gebhardt M, Springfield D, Kusuzaki K, Mankin H . Experimental models for the study of drug resistance in osteosarcoma: P-glycoprotein-positive, murine osteosarcoma cell lines. J Bone Joint Surg Am. 1996; 78(3):366-75. DOI: 10.2106/00004623-199603000-00007. View